IN10018 with dalpiciclib for meningiomas that keep growing
Official title: IN10018 in Combination With Dalpiciclib for Progressive Meningiomas
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests two drugs, taken by mouth, in adults whose meningioma has kept growing or has come back.
Read our full plain-language summary
What the trial team says
This open-label Phase Ib study will evaluate the safety, tolerability, and preliminary effectiveness of IN10018 in combination with dalpiciclib in adults with progressive meningiomas. Progressive meningiomas are tumors arising from the membranes surrounding the brain that have continued to grow or have returned after previous treatment. Participants will receive both study drugs by mouth in 28-day treatment cycles. IN10018 will be taken once daily throughout each cycle, and dalpiciclib will be taken once daily for 21 days followed by 7 days without dalpiciclib. Treatment may continue until the tumor progresses, unacceptable side effects occur, or another reason for stopping treatment applies. The study includes a dose-confirmation phase and a dose-expansion phase. The main goals are to evaluate side effects and determine a recommended dose of the combination for further study. Researchers will also assess whether the treatment can shrink tumors or delay tumor growth, measure how the drugs are processed in the body, and explore tumor and blood biomarkers that may be associated with treatment response.
Key facts
- Registry number
- NCT07652762
- Stage of testing
- Phase 1
- Conditions studied
- Meningioma, CDK4/6 Inhibitor
Where it is running
This trial lists 2 sites.
-
Beijing Municipality
- Beijing Sanbo Brain Hospital, Capital Medical University (Beijing)
-
China
- Sanbo Brain Hospital, Capital Medical University (Beijing)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.